Orally active iron chelators

Area of Science:

• Hematology
• Pharmacology
• Toxicology

Background:

• Iron accumulation is a fatal complication in transfusion-dependent anemias without chelation therapy.
• Parenteral deferoxamine offers extended survival but its cost and inconvenience drive the search for oral alternatives.
• Deferiprone, an orally active iron chelator, has raised concerns regarding its efficacy and safety.

Purpose of the Study:

• To evaluate the effectiveness and safety of deferiprone as an oral iron chelator in transfusion-dependent anemia patients.
• To compare the outcomes of deferiprone treatment with established therapies like deferoxamine.
• To assess the potential risks associated with deferiprone, including cardiac and hepatic complications.

Main Methods:

• Review of studies evaluating long-term deferiprone treatment in patients with transfusion-dependent anemias.
• Analysis of data on hepatic iron levels and patient outcomes following deferiprone administration.
• Assessment of reported cardiac and liver disease complications in patients treated with deferiprone.

Main Results:

• Studies indicate that 18-65% of patients on long-term deferiprone treatment have iron levels exceeding the threshold for cardiac disease and premature death.
• The impact of deferiprone on cardiac and liver disease requires further investigation.
• An association between deferiprone and accelerated hepatic fibrosis needs to be refuted in large prospective trials.

Conclusions:

• Deferiprone's effectiveness is questionable in a significant patient subset, with risks of severe iron overload complications.
• Deferoxamine's long-term success warrants reconsideration of deferiprone use outside prospective clinical trials.
• Development of a safe and effective oral iron chelator remains a critical objective for managing transfused patients.